News & Updates

Show Multimedia Only

An aspirin a day does not keep melanoma at bay

13 Jul 2022

Taking aspirin daily appears to do nothing in terms of reducing the risk of cutaneous melanoma in older individuals, according to a study.

13 Jul 2022

Can very low-risk breast cancer patients be spared from postop radiotherapy?

12 Jul 2022 by

Adjuvant radiotherapy (RT) may be omitted in women with very low-risk breast cancer who have had breast conserving surgery (BCS) and have been receiving endocrine therapy, according to findings from the LUMINA study.

12 Jul 2022

Immune checkpoint inhibitors linked to increased major cardiac events in the real world

12 Jul 2022 by

Treatment with immune checkpoint inhibitors (ICIs) in real-world settings is associated with a higher incidence of adverse cardiovascular events than traditionally reported in clinical trials, a retrospective cohort study has shown. Patients at risk include those with a history of cardiovascular disease (CVD), especially a history of heart failure (HF) or valvular heart disease (VHD).

12 Jul 2022

Risk factors for metastatic cutaneous SCC may help refine staging systems

11 Jul 2022 by

The inclusion of nonlinear relationships for diameter and thickness, clinical characteristics such as sex and tumour location, and differentiation can improve the staging systems of cutaneous squamous cell carcinoma (cSCC), suggests a recent study.

11 Jul 2022

Sabizabulin for metastatic castration-resistant prostate cancer clears phase early trial

10 Jul 2022

The oral cytoskeleton disruptor sabizabulin shows antitumour activity in men with metastatic castration-resistant prostate cancer, while having a favourable safety profile, as shown in the results of a phase Ib/II trial.

10 Jul 2022

Which nonexcisional treatment modality is best for squamous cell carcinoma?

09 Jul 2022

Use of photodynamic therapy, 5-fluorouracil, or imiquimod is not as effective as electrodessication and cryotherapy, in combination with curettage, in the treatment of squamous cell carcinoma in situ (SCCIS) and squamous cell carcinoma (SCC), results of a study have shown.

09 Jul 2022

Quizartinib bounces back, doubles OS in FLT3-ITD-positive AML

09 Jul 2022 by

The oral FLT3 inhibitor quizartinib more than doubled overall survival (OS) when added to first-line chemotherapy in patients with newly diagnosed FLT3-ITD*-positive acute myeloid leukaemia (AML) in the phase III QuANTUM-First** trial

09 Jul 2022